Uncategorized

AIDS activists ask AVEXA not to leave patients behind

June 17, 2010 Dr. Susan Cox Former Senior Vice President, Drug Development at Avexa Cc: Nathan Drona, Chairman of the Board at Avexa      Stephen Kerr, Board Secretary We, the undersigned, are asking the decision makers at Avexa to reconsider the decision to stop the development of apricitabine, a nucleoside analog that has shown good efficacy in …

AIDS activists ask AVEXA not to leave patients behind Read More »

HIV Salvage Patients Are Concerned About Recent Pharma Decisions

I am scared that companies are dropping new HIV medications Jun 17, 2010 Nelson, I emailed you before and you told me there were a few medications in research for people with resistance to all meds. But I just heard that two companies abandoned their research. What does that mean for someone like me who …

HIV Salvage Patients Are Concerned About Recent Pharma Decisions Read More »

AIDS Activists Support the Approval of Egrifta- But Some Conditions for Theratecnologies and Serono

17 May 2010 Paul Tran, BS Pharrn, RPh Advisors and Consultants Staff Center for Drug Evaluation and Research Food and Drug Administration 5630 Fishers Lane, HFD-21 Rockville, MD 20857 Dear Mr. Tran: On behalf ofthe Drug Development Committee (DDC) ofthe AIDS Treatment Activists Coalition (ATAC), I am writing to urge members ofthe Endocrinologic and Metabolic …

AIDS Activists Support the Approval of Egrifta- But Some Conditions for Theratecnologies and Serono Read More »

AIDS Activists Support the Approval of Egrifta- But With Some Conditions for Theratecnologies and Serono

17 May 2010 Paul Tran, BS Pharrn, RPh Advisors and Consultants Staff Center for Drug Evaluation and Research Food and Drug Administration 5630 Fishers Lane, HFD-21 Rockville, MD 20857 Dear Mr. Tran: On behalf ofthe Drug Development Committee (DDC) ofthe AIDS Treatment Activists Coalition (ATAC), I am writing to urge members ofthe Endocrinologic and Metabolic …

AIDS Activists Support the Approval of Egrifta- But With Some Conditions for Theratecnologies and Serono Read More »

Survey: Most patients with HIV lipodystrophy are willing to inject Egrifta once a day to reduce their visceral fat

 LIPODYSTROPHY TREATMENT- PATIENT ACCEPTANCE DownloadCreate Chart1. Has your belly fat increased after starting HIV medications? answered question 85 skipped question 2 Response Percent Response Count Yes 92.9% 79 No 7.1% 6 DownloadCreate Chart2. Would you be willing to inject a drug daily under your skin in your belly to decrease your belly fat by 13% …

Survey: Most patients with HIV lipodystrophy are willing to inject Egrifta once a day to reduce their visceral fat Read More »

Impact of Lipodystrophy on Quality of Life of People Living With HIV- Survey Results

1. How old are you? answered question 1,325 skipped question 6 ResponsePercent ResponseCount Under 15 years old 0.3% 4 15-20 0.2% 2 20-25 0.5% 7 25-30 1.7% 23 30-35 4.8% 63 35-40 7.8% 104 40-45 23.1% 306 45-50 22.6% 299 50-55 20.8% 275 55-60 11.4% 151 Over 60 6.9% 91 DownloadCreate Chart2. What is your …

Impact of Lipodystrophy on Quality of Life of People Living With HIV- Survey Results Read More »

FDA Committee Unanimously Recommends Egrifta for Lipodystrophy

FROM POZ.COM May 27, 2010 FDA Committee Unanimously Recommends Egrifta for Lipodystrophy A U.S. Food and Drug Administration (FDA) advisory committee has unanimously recommended that Egrifta (tesamorelin), Montreal-based Theratechnologies’ experimental product for the treatment of excess abdominal fat in HIV-positive people with lipodystrophy, be approved by the agency.  Though the FDA is not required to …

FDA Committee Unanimously Recommends Egrifta for Lipodystrophy Read More »

Vitamin and Mineral Use in HIV- Summary of Studies

 Excellent summary tables on the use of micronutrients in HIV published in Am J Clin Nutr 2007;85:333–45. Printed in USA. © 2007 American Society for Nutrition https://www.ajcn.org/cgi/content/full/85/2/333 Reference Study design, location, and population Vitamin concentrations1 Results and conclusions Cross-sectional studies     Toma et al, 2001 (93) Cross-sectional study in Canada. 11 HIV-positive adults (6 receiving HAART …

Vitamin and Mineral Use in HIV- Summary of Studies Read More »